nintedanib

P=N/A, N=585, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

P2, N=33, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Apr 2024 | Trial primary completion date: Jul 2025 --> Apr 2024

P4, N=103, Completed, Icahn School of Medicine at Mount Sinai | Active, not recruiting --> Completed

We further pinpoint reduced SMAD3 expression and consequent limited TIMP-1 production in SCC-TAFs as key for the resistance of SCC to nintedanib. These observations strongly support the emerging role of TIMP-1 as a critical regulator of therapy response in solid tumors.

GPS and BMI were significant factors for short-term pirfenidone and nintedanib discontinuation, respectively. Initial evaluation of GPS and BMI prior to antifibrotic therapy may contribute to less interrupted IPF management, thus leading to better prognostic outcomes in patients with IPF.

Nintedanib inhibits the proliferation, invasion, and metastasis of gastric cancer cells. The crossover pathways and protein networks predicted by proteomics should provide more detailed molecular information enabling the use of nintedanib against gastric cancer.

P2, N=20, Recruiting, University Hospital, Basel, Switzerland | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

In addition, nintedanib exhibited an anti-osteosarcoma effect on C57BL/6 severe combined immunodeficient mice in which T- and B-cell function is obsolete, suggesting that the antitumor effect of nintedanib was not attributable to antitumor immunity. Collectively, these findings indicated that nintedanib holds potential for treating osteosarcoma.

P1/2, N=56, Completed, AIO-Studien-gGmbH | Active, not recruiting --> Completed

The use of the antifibrotic drugs pirfenidone and nintedanib can slow the progression of the disease to some extent, but it does not have a reverse effect on the prognosis. While current studies have focused on PD-1/PD-L1 and CTLA-4, PD-1/PD-L1 may be the only effective immune checkpoint IPF treatment. This review discusses the application of PD-1/PD-L1 checkpoint in IPF, with the aim of finding a new direction for IPF treatment.

P2, N=20, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Dec 2024

P3, N=53, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

P=N/A, N=100, Not yet recruiting, Boehringer Ingelheim

P=N/A, N=0, Withdrawn, Boehringer Ingelheim | N=800 --> 0 | Not yet recruiting --> Withdrawn

Nintedanib may be effective for improving clinical symptoms, laboratory parameters, lung lesions, and survival in anti-MDA5+ DM. Diarrhoea was the most common adverse event associated with nintedanib, although the drug was well tolerated by most patients.

P1, N=14, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed

P1, N=44, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jan 2027 | Trial primary completion date: Mar 2023 --> Dec 2025

P1/2, N=68, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2024

In this study, we reported that high PD-L1 modulates STAT signaling in the presence of PBMC and induces pro-angiogenic factor secretion. This could enforce the role of PD-L1 as a crucial regulator of the tumor microenvironment stimulating tumor progression, both as an inhibitor of T-cell activity and as a promoter of tumor angiogenesis.

P3, N=60, Recruiting, Boehringer Ingelheim | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

P=N/A, N=816, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

The average monthly cost for the treatment of neoplastic diseases was $17,900 with a price of $44,000 for futibatinib (used to treat cholangiocarcinomas with FGFR2 fusions) and minimum of $5100 for binimetinib (melanoma). The average monthly cost for the treatment of non-neoplastic diseases was $6800 with a maximum of $17,000 for belumosudil (graft vs. host disease) and a minimum of $200 for netarsudil eye drops (glaucoma). There is a negative correlation of the cost of the drugs and the incidence of the targeted disease. Many of these agents are or were designated as orphan drugs meaning that there are fewer than 200,000 potential patients in the United States.

P1, N=14, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

P=N/A, N=123, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P=N/A, N=10117, Completed, Boehringer Ingelheim | Recruiting --> Completed | N=6000 --> 10117 | Trial completion date: Nov 2023 --> May 2023 | Trial primary completion date: Nov 2023 --> May 2023

No abstract available

P1, N=14, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting

P=N/A, N=550, Recruiting, Boehringer Ingelheim | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

Among early HER2negBC, Luminal B cases display the highest MeCo Scores. MeCo Score was independent of all classic prognostic variables. High MeCo Score is associated with lack of pCR to neoadjuvant paclitaxel monotherapy, but concurrent administration of the anti-fibrotic agent nintedanib rescues this association.

P2, N=20, Not yet recruiting, China Medical University Hospital

P1, N=14, Not yet recruiting, Boehringer Ingelheim

P2, N=20, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jun 2023 --> Dec 2023

Brain metastases were present in 19.9% (47/236) of pts and 86.4% (204/236) had received prior 1L pembrolizumab-based combination therapy. NIN + DOC is an effective and safe 2L treatment option after prior 1L ICI + chemotherapy for NSCLC adenocarcinoma pts independent of KRAS status.

Nintedanib significantly enhanced the anti-tumor effects of RIT with the 90Y-B5209B without an increase in toxicity. These findings encourage further research into the potential clinical application of combining RIT with nintedanib.

To our knowledge, this study is the first biomarker-driven umbrella trial for platinum-refractory HNSCC using matched molecular targeted agents. We found that NGS-based genomic phenotyping was methodologically feasible and applicable.

The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.

Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib.

In comparison to parental GIST-T1, GIST-BSF1 treated with SCF displayed 4.3-29.3-fold higher GR50-values for all tested KIT inhibitors, except for sunitinib (1.4-fold) and nintedanib (3.1-fold)...GIST-BSF1 sublines with secondary mutations in-cis in both the ATP binding pocket (AP) and activation loop (AL) of KIT, called AP/AL mutations, display the same inhibitory profile towards ripretinib as seen in AP/AL mutations previously modelled in GIST-T1 (GR50 values for AP/AL mutants >20-fold higher than corresponding AL mutants)... GIST-BSF1 is the first KIT-WT, SCF-dependent GIST cell line, which allows study of the impact of KIT inhibitors on WT KIT. Reintroduction of KIT mutations leads to SCF-independent growth and yielded anticipated TKI profiles. This cell line platform allows the rapid validation of novel variants of KIT and other oncogenic kinases in a GIST-specific cellular background.

Lung cancer is prevalent in IPF. Management of patients with IPF and lung cancer is challenging. A consensus statement aiming to attenuate confusion is greatly anticipated.